Next Article in Journal
SP-8356, a Novel Inhibitor of CD147-Cyclophilin A Interactions, Reduces Plaque Progression and Stabilizes Vulnerable Plaques in apoE-Deficient Mice
Next Article in Special Issue
The Cannabis Proteome Draft Map Project
Previous Article in Journal
Correction of RNA-Binding Protein CUGBP1 and GSK3β Signaling as Therapeutic Approach for Congenital and Adult Myotonic Dystrophy Type 1
Previous Article in Special Issue
Proteomic Analysis of Quercetin-Treated K562 Cells
Review

Urinary Peptidomic Biomarkers in Kidney Diseases

1
Nephrology and Dialysis Unit, Department of Medicine, G. d’Annunzio University, Chieti-Pescara, SS.Annunziata Hospital, Via dei Vestini, 66013 Chieti, Italy
2
Proteomics and Metabonomics Unit, IRCCS Fondazione Santa Lucia, 00179 Rome, Italy
3
Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, 00168 Rome, Italy
4
Department of Laboratory Diagnostic and Infectious Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(1), 96; https://doi.org/10.3390/ijms21010096
Received: 30 November 2019 / Revised: 16 December 2019 / Accepted: 19 December 2019 / Published: 21 December 2019
(This article belongs to the Collection Advances in Proteomic Research)
In order to effectively develop personalized medicine for kidney diseases we urgently need to develop highly accurate biomarkers for use in the clinic, since current biomarkers of kidney damage (changes in serum creatinine and/or urine albumin excretion) apply to a later stage of disease, lack accuracy, and are not connected with molecular pathophysiology. Analysis of urine peptide content (urinary peptidomics) has emerged as one of the most attractive areas in disease biomarker discovery. Urinary peptidome analysis allows the detection of short and long-term physiological or pathological changes occurring within the kidney. Urinary peptidomics has been applied extensively for several years now in renal patients, and may greatly improve kidney disease management by supporting earlier and more accurate detection, prognostic assessment, and prediction of response to treatment. It also promises better understanding of kidney disease pathophysiology, and has been proposed as a “liquid biopsy” to discriminate various types of renal disorders. Furthermore, proteins being the major drug targets, peptidome analysis may allow one to evaluate the effects of therapies at the protein signaling pathway level. We here review the most recent findings on urinary peptidomics in the setting of the most common kidney diseases. View Full-Text
Keywords: kidney; urine; peptidomics; biomarker; CKD; clinical proteomics; mass spectrometry kidney; urine; peptidomics; biomarker; CKD; clinical proteomics; mass spectrometry
Show Figures

Graphical abstract

MDPI and ACS Style

Sirolli, V.; Pieroni, L.; Di Liberato, L.; Urbani, A.; Bonomini, M. Urinary Peptidomic Biomarkers in Kidney Diseases. Int. J. Mol. Sci. 2020, 21, 96. https://doi.org/10.3390/ijms21010096

AMA Style

Sirolli V, Pieroni L, Di Liberato L, Urbani A, Bonomini M. Urinary Peptidomic Biomarkers in Kidney Diseases. International Journal of Molecular Sciences. 2020; 21(1):96. https://doi.org/10.3390/ijms21010096

Chicago/Turabian Style

Sirolli, Vittorio, Luisa Pieroni, Lorenzo Di Liberato, Andrea Urbani, and Mario Bonomini. 2020. "Urinary Peptidomic Biomarkers in Kidney Diseases" International Journal of Molecular Sciences 21, no. 1: 96. https://doi.org/10.3390/ijms21010096

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop